Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

Perspective AI emerged from stealth today to announce a $4 million seed funding round led by Village Global, Array Ventures, Honeystone VC, Recursive Ventures, Darkmode VC, and prominent angel ...

I have had the great privilege of serving my local health system as Medical Director for Home Hospice. Every week I sit in a ...

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...

Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...

CIA’s Master’s in Culinary Therapeutics. Hyde Park, NY, January 27, 2025 – CIA has introduced a first-of-its-kind Culinary ...

Perspective Therapeutics Inc (CATX) stock saw a modest uptick, ending the day at $4.01 which represents a slight increase of $0.38 or 10.47% from the prior close of $3.63. The stock opened at $3.64 ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research ...